NIMH Chemical Synthesis & Drug Supply Program

镍氢化学合成

• 批准号: 8845043
• 负责人: KENNETH REHDER
• 金额: $ 12万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-02-27 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8845043
• 关键词: Agonist; Area; Award; Basic Science; Behavioral; Biochemical; Brain imaging; Clinical Research; Clinical Trials; Contractor; Contracts; Fees; Functional Magnetic Resonance Imaging; Funding; Human; Legal patent; Ligands; Longitudinal Studies; Mental Health; Molecular; National Institute of Mental Health; Neuraxis; Performance; Pharmaceutical Preparations; Pharmacology; Positron-Emission Tomography; Primates; Psychotropic Drugs; Radiolabeled; Signal Transduction; Source; chemical synthesis; novel; programs; radiotracer; receptor; single photon emission computed tomography

The purpose of the NIMH Chemical Synthesis and Drug Supply Program is to synthesize, purify, and provide essential compounds that are unavailable from commercial sources (e.g., the stock has been depleted and it will not be replenished, patented compounds that are unavailable while undergoing clinical trials, etc.) to stimulate basic and clinical research relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in primates and humans. The present initiative focuses on the synthesis of current GMP (Good Manufacturing Practices) and non-GMP compounds for basic and clinical research such as novel central nervous system receptor subtype-selective agonists and antagonists, radiolabeled compounds, and novel PET, SPECT, and fMRI ligands for functional brain imaging.

NIMH化学合成和药物供应计划的目的是合成、纯化和提供商业来源无法获得的必需化合物（例如库存已耗尽且不会补充、正在进行临床试验时无法获得的专利化合物等），以促进与中枢神经系统分子药理学和信号传导等领域的精神健康相关的基础和临床研究 受体，评估精神活性化合物的分子、生化和行为作用的纵向研究，以及灵长类动物和人类的功能性脑成像。目前的计划重点是合成用于基础和临床研究的现行 GMP（良好生产规范）和非 GMP 化合物，例如新型中枢神经系统受体亚型选择性激动剂和拮抗剂、放射性标记化合物以及用于功能性脑成像的新型 PET、SPECT 和 fMRI 配体。